WuXi Biologics– tag –
-
Transcenta Therapeutics and WuXi Biologics Forge Strategic Alliance to Expedite Commercialization of HiCB Continuous Bioprocessing Technologies
BioSpace USA Overview Transcenta Therapeutics and WuXi Biologics have entered a strategic collaboration to accelerate the commercialization and deployment of Transcenta's proprietary High-Intensity Continuous Bioprocessing (HiCB) platfor... -
WuXi Biologics Breaks Ground on $1.4 Billion CRDMO Center in Singapore, Boosting Global Manufacturing Capacity by 120,000 Liters
EDB Singapore China Overview WuXi Biologics has broken ground on a new $1.4 billion Contract Research, Development, and Manufacturing Organization (CRDMO) center in Singapore's Tuas Biomedical Park. This massive investment will add 120,0... -
WuXi Biologics Reports 18.4% H1 2026 Revenue Growth and 300 IND Application Capacity Annually, Driven by Low-Cost Strategy
Seeking Alpha China Overview WuXi Biologics announced robust financial results for H1 2026, with revenue increasing by 18.4%, primarily driven by demand for investigational drugs and multi-specific antibodies. The company has expanded it... -
Continuous Upstream Bioprocessing Gains Traction, WuXi Biologics Pioneers Fully Automated Perfusion Platform for Enhanced Productivity
Pharma Manufacturing USA Overview Continuous upstream bioprocessing, especially perfusion culture, is significantly enhancing productivity and consistency in biomanufacturing. CDMOs are increasing investments in continuous bioprocessing ... -
Perfusion Cell Culture Patents 2026: Top 5 Assignees Hold 79.2% Share, Hardware and Cell Line Engineering Dominate Claims
Patsnap Germany Overview A patent analysis based on mid-2026 data reveals that 79.2% of patent activity in perfusion and intensified cell culture technologies is concentrated among the top five assignees. These patents primarily cover ha... -
Perfusion Bioreactor Adoption Doubles to 65.8% Since 2016, Accelerating Shift to Continuous Biomanufacturing
synbio.intel USA Overview A BioPlan Associates survey from August 2026 reveals that single-use perfusion equipment usage has doubled to 65.8% across all production stages since 2016, indicating an accelerating shift towards continuous bi... -
Market Report: Global Single-Use Bioreactor Market to Surge, Thermo Fisher and AGC Biologics Expand Capacity
GlobeNewswire Global Overview This article summarizes the market research report "Global Single-use Bioreactors Market Forecast to Surge from USD 3.61 Billion in 2025 to USD 15.11 Billion by 2034." The global single-use bioreactors marke... -
Digital Biomanufacturing Market Projected to Reach $66.14 Billion by 2034, Driven by Automation and AI: Market Research Report
Fortune Business Insights Global Overview This article summarizes a Digital Biomanufacturing Market research report from Fortune Business Insights. The report projects the digital biomanufacturing market will reach $66.14 billion by 2034... -
Pharmaceutical CDMO Market Report: Capital Investments and Advanced Therapies Drive Growth
Global Market Insights Global Overview This article provides an overview of the Pharmaceutical CDMO Market research report published by Global Market Insights. The report highlights significant capital investments and major expansions wi... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The...
12